HROW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

HR

Mkt Cap

$1.02B

Volume

470.92K

Next Earnings

November 9th

Loading chart

HR

HROWHarrow, Inc. Common Stock

HROW

Pay with—

Available Balance0.00

HR

Mkt Cap

$1.02B

Volume

470.92K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Do Options Traders Know Something About Harrow Stock We Don't?Harrow, Inc. (HROW) is drawing attention due to high implied volatility in its October 2026 $15.00 call options, suggesting traders expect significant price movement. However, the company holds a Zacks Rank #3 (Hold) rating in the Medical-Drugs industry, with analyst consensus estimates declining from 94 cents to 87 cents per share over the last 60 days. The elevated implied volatility may present opportunities for premium-selling strategies rather than directional bets.Zacks Investment Research · Oct 9, 2026

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingHarrow announced presentations of three studies supporting its ophthalmic products IHEEZO (chloroprocaine HCl ophthalmic gel) and BYOOVIZ (ranibizumab-nuna biosimilar) at the ASRS 2026 Annual Meeting. Interim findings from a randomized study showed IHEEZO demonstrated encouraging trends toward less post-injection pain and better patient experience compared to subconjunctival lidocaine. A large real-world analysis of nearly 20,000 injections found no increased endophthalmitis risk with IHEEZO. The company continues enrollment in the QUELL clinical trial with topline data expected in Q4 2026.GlobeNewswire Inc. · Jul 20, 2026

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareHarrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses underlying inflammatory mechanisms and reduces the need for steroid rescue therapy, which carries risks like glaucoma and cataract formation.GlobeNewswire Inc. · Jun 10, 2026

Harrow to Present at William Blair’s 46th Annual Growth Stock ConferenceHarrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, announced that management will present at William Blair's 46th Annual Growth Stock Conference on June 3, 2026, in Chicago. The presentation will be webcast live with a 90-day replay available on the company's website.GlobeNewswire Inc. · May 27, 2026

Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030Harrow (Nasdaq: HROW), an ophthalmic disease management solutions provider, announced a private offering of $50 million in 8.625% senior unsecured notes due 2030. The notes will be issued as additional notes under the same indenture as $250 million in existing notes issued in September 2025. The offering is expected to close on March 27, 2026, with net proceeds intended for general corporate purposes including new product launches, product development, and strategic business development opportunities.GlobeNewswire Inc. · Mar 24, 2026

A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?Opaleye Management Inc., a 10% owner of ophthalmic pharma company Harrow, sold 198,572 shares worth $7.8 million on March 3-4, 2026. However, the fund retained approximately 3.7 million shares (nearly 10% ownership), suggesting this was a tactical profit-taking move following post-earnings weakness rather than a strategic exit.The Motley Fool · Mar 24, 2026

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026Harrow announced it will report Q4 and full-year 2025 financial results on March 2, 2026, with a conference call scheduled for March 3, 2026. The company reaffirmed its 2025 full-year revenue guidance of $270-$280 million, indicating strong growth. Harrow is expanding its commercial footprint across multiple product lines including VEVYE, IHEEZO, and TRIESENCE.GlobeNewswire Inc. · Feb 18, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong GrowthHarrow reaffirmed its 2025 revenue guidance of $270-280 million and announced multiple growth initiatives including doubling its VEVYE sales force, expanding IHEEZO to office-based settings, and doubling TRIESENCE's surgical sales force. The company launched the OneHarrow initiative to unify branding, promoted Patrick W. Sullivan to Chief Commercial Officer, and advanced MELT-300 and MELT-210 toward NDA filings. ImprimisRx settled regulatory matters with California and exited the state market.GlobeNewswire Inc. · Feb 2, 2026

Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue SurgePenn Capital Management sold 1.6 million shares of BGC Group in Q3, reducing its stake to $5.9 million, despite the company reporting record quarterly revenue of $736.8 million, up 31% year-over-year.The Motley Fool · Nov 27, 2025

Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever?Harrow Inc. announced the acquisition of Melt Pharmaceuticals, a clinical-stage company developing a non-opioid sedation tablet (MELT-300) for medical procedures. The company plans to submit a New Drug Application to the FDA in 2027, targeting a U.S. launch in 2028.Benzinga · Sep 26, 2025

to start trading

HR

HROWHarrow, Inc. Common Stock

HROW

Pay with—

Available Balance0.00

Your PositionYou don't own any HROW yet.

Related Tickers

Earnings